196 related articles for article (PubMed ID: 37765274)
1. A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia.
Chen M; Fang X; Du R; Meng J; Liu J; Liu M; Yang Y; Wang C
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765274
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
Yong AS; Keyvanfar K; Eniafe R; Savani BN; Rezvani K; Sloand EM; Goldman JM; Barrett AJ
Leukemia; 2008 Sep; 22(9):1721-7. PubMed ID: 18548092
[TBL] [Abstract][Full Text] [Related]
4. [Expression of Wilms' tumor gene (WT1) in leukemias and its clinical implication].
Wu X; Wang Y; Pei X
Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):16-9. PubMed ID: 10921096
[TBL] [Abstract][Full Text] [Related]
5. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
6. Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia.
Szántó A; Pap Z; Dénes L; Benedek Lázár E; Horváth A; Tunyogi AB; Baróti BÁ; Pávai Z
Rom J Morphol Embryol; 2015; 56(2 Suppl):703-7. PubMed ID: 26429162
[TBL] [Abstract][Full Text] [Related]
7. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
[TBL] [Abstract][Full Text] [Related]
8. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.
Menssen HD; Renkl HJ; Rodeck U; Maurer J; Notter M; Schwartz S; Reinhardt R; Thiel E
Leukemia; 1995 Jun; 9(6):1060-7. PubMed ID: 7596170
[TBL] [Abstract][Full Text] [Related]
9. [Bone marrow WT1 gene expression and clinical significance in chronic myelogenous leukemia].
Cao XS; Gu WY; Chen ZX; Hu SY; He J; Cen JN
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):277-9. PubMed ID: 17637262
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions.
Luo P; Jing W; Yi K; Wu S; Zhou F
Leuk Lymphoma; 2020 Sep; 61(9):2059-2067. PubMed ID: 32401109
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients.
Wei L; Zuo H; Sun X; Liu T; Guo M; Liu G; Sun Q; Qiao J; Wang D; Yu C; Hu K; Dong Z; Ai H
Int J Hematol; 2010 May; 91(4):652-60. PubMed ID: 20376582
[TBL] [Abstract][Full Text] [Related]
12. Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias.
Kreuzer KA; Saborowski A; Lupberger J; Appelt C; Na IK; le Coutre P; Schmidt CA
Br J Haematol; 2001 Aug; 114(2):313-8. PubMed ID: 11529849
[TBL] [Abstract][Full Text] [Related]
13. Studies of WT1 gene expression in leukemia patients.
Huang Z; Xiao B; Chen S; Li S; Liu Y; Liu J
Zhonghua Xue Ye Xue Za Zhi; 2002 Jul; 23(7):367-9. PubMed ID: 12411055
[TBL] [Abstract][Full Text] [Related]
14. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
15. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase.
Narita M; Masuko M; Kurasaki T; Kitajima T; Takenouchi S; Saitoh A; Watanabe N; Furukawa T; Toba K; Fuse I; Aizawa Y; Kawakami M; Oka Y; Sugiyama H; Takahashi M
Int J Med Sci; 2010 Apr; 7(2):72-81. PubMed ID: 20428337
[TBL] [Abstract][Full Text] [Related]
16. Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia.
Carapeti M; Goldman JM; Cross NC
Eur J Haematol; 1997 May; 58(5):346-9. PubMed ID: 9222290
[TBL] [Abstract][Full Text] [Related]
17. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
[TBL] [Abstract][Full Text] [Related]
19. BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.
Parry N; Busch C; Aßmann V; Cassels J; Hair A; Helgason GV; Wheadon H; Copland M
Cell Death Discov; 2022 Nov; 8(1):457. PubMed ID: 36379918
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for leukemia targeting the Wilms' tumor gene.
Yasukawa M
Leuk Lymphoma; 2001 Jul; 42(3):267-73. PubMed ID: 11699391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
